Literature DB >> 6575218

Glucocorticoid receptor level, terminal deoxynucleotidyl transferase activity and initial responsiveness to prednisone and vincristine in leukemia.

A D Ho, S Stojakowits, H Pralle, M Dörner, W Hunstein.   

Abstract

We have investigated glucocorticoid receptor (GR) level, terminal deoxynucleotidyl transferase (TdT) activity and the initial responsiveness to prednisone and vincristine in 31 patients with acute lymphatic leukemia (ALL) and with chronic myelogenous leukemia in blast transformation (CML/BT). All 11 patients with low levels of GR (5,000 binding sites per cell) were resistant to this initial treatment whereas 13 of the 20 patients with high levels of GR responded readily. The correlations between clinical responsiveness and TdT activity were significant to the p less than 0.005 level but there was no linear correlation (r = 0.3427) between GR-level and TdT activity. High levels of both GR and TdT seemed to be associated with better prognosis in patients with these leukemias. Thus the determination of GR and TdT might help selection of patients likely to respond to prednisone and vincristine in ALL and CML/BT.

Entities:  

Mesh:

Substances:

Year:  1983        PMID: 6575218     DOI: 10.1007/bf02664333

Source DB:  PubMed          Journal:  Klin Wochenschr        ISSN: 0023-2173


  22 in total

1.  Glucocorticoid receptors and sensitivity of isolated human leukemia and lymphoma cells.

Authors:  G R Crabtree; K A Smith; A Munck
Journal:  Cancer Res       Date:  1978-11       Impact factor: 12.701

Review 2.  Treatment of acute leukemia.

Authors:  E S Henderson
Journal:  Semin Hematol       Date:  1969-07       Impact factor: 3.851

3.  Clinical implications of glucocorticoid receptors in human leukemia.

Authors:  M E Lippman; G K Yarbro; B G Leventhal
Journal:  Cancer Res       Date:  1978-11       Impact factor: 12.701

4.  Clinical implications of glucocorticoid receptor studies in childhood acute lymphoblastic leukemia.

Authors:  R Mastrangelo; R Malandrino; R Riccardi; P Longo; F O Ranelletti; S Iacobelli
Journal:  Blood       Date:  1980-12       Impact factor: 22.113

5.  Correlation between glucocorticoid receptor and cytolytic response of murine lymphoid cell lines.

Authors:  S Bourgeois; R F Newby
Journal:  Cancer Res       Date:  1979-11       Impact factor: 12.701

6.  Glucocorticoid receptors in lymphoma cells in culture: relationship to glucocorticoid killing activity.

Authors:  J D Baxter; A W Harris; G M Tomkins; M Cohn
Journal:  Science       Date:  1971-01-15       Impact factor: 47.728

7.  Glucocorticoid receptors and glucocorticoid sensitivity of human leukemic cells.

Authors:  K Kontula; L C Andersson; T Paavonen; G Myllylä; L Teerenhovi; P Vuopio
Journal:  Int J Cancer       Date:  1980-08       Impact factor: 7.396

8.  Glucocorticoid receptor concentrations and terminal transferase activity as indicators of prognosis in acute non-lymphocytic leukaemia.

Authors:  L Skoog; B Nordenskjöld; A Ost; B Andersson; R Hast; N Giannoulis; S Humla; T Hägerström; P Reizenstein
Journal:  Br Med J (Clin Res Ed)       Date:  1981-06-06

9.  Murine terminal deoxynucleotidyl transferase: cellular distribution and response to cortisone.

Authors:  P C Kung; A E Siverstone; R P McCaffrey; D Baltimore
Journal:  J Exp Med       Date:  1975-04-01       Impact factor: 14.307

10.  Terminal deoxynucleotidyl transferase activities and glucocorticoid receptors in leukaemia.

Authors:  R Sasaki; F Takaku; T Aoki; F J Bollum; T Saito; S Dan
Journal:  Br J Cancer       Date:  1981-07       Impact factor: 7.640

View more
  2 in total

1.  [Clinical relevance of glucocorticoid receptors in the treatment of lymphoid neoplasias].

Authors:  U Gehring; A D Ho
Journal:  Klin Wochenschr       Date:  1987-03-16

2.  Impact of glucocorticoid receptor density on ligand-independent dimerization, cooperative ligand-binding and basal priming of transactivation: a cell culture model.

Authors:  Steven Robertson; Johann M Rohwer; Janet P Hapgood; Ann Louw
Journal:  PLoS One       Date:  2013-05-22       Impact factor: 3.240

  2 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.